Mosunetuzumab plus polatuzumab vedotin achieved a 100% overall response rate in Japanese patients with LBCL
Trial shows promising results for relapsed large B-cell lymphoma
This Phase III randomized controlled trial analyzed a subgroup of 16 Japanese patients with relapsed or refractory large B-cell lymphoma. Th…
A new treatment combination showed a high response rate and longer progression-free survival for patients with a specific type of lymphoma.
Axicabtagene ciloleucel shows higher early response but greater toxicity than tisagenlecleucel in large B-cell lymphoma
Comparison of two CAR-T cell therapies for lymphoma
This meta-analysis compared axicabtagene ciloleucel and tisagenlecleucel for the treatment of large B-cell lymphoma. While axicabtagene cilo…
New data comparing axicabtagene ciloleucel and tisagenlecleucel shows different levels of early response and safety risks for lymphoma patie…
Systematic review and meta-analysis of interim FDG PET in large B-cell lymphoma patients
Early PET scans help doctors predict how well large B-cell lymphoma treatments will work for patients
This systematic review and meta-analysis evaluated the utility of interim FDG PET (iPET) in 44 eligible studies involving large B-cell lymph…
A review of many studies shows that early PET scans can tell doctors if cancer treatment is working. This helps them decide the best next st…
Research across Cancer
Related studies from across the Cancer family.
VRE Prevalence 18.4% in Hematologic Malignancy Patients, Pooled Meta-Analysis Finds
Vancomycin-resistant Enterococcus is common in patients with certain blood cancers
This meta-analysis of 120 studies estimates the pooled prevalence of vancomycin-resistant Enterococcus (VRE) in patients with hematological …
A large review of 120 studies shows that nearly 1 in 5 patients with leukemia or lymphoma carry a resistant strain of bacteria.
Evaluating Cytokine and Molecular Biomarkers for Diagnosing Primary Vitreoretinal Lymphoma
Biomarkers Show Promise in Detecting Vitreoretinal Lymphoma
A meta-analysis identifies the IL-10 to IL-6 ratio and MYD88 as high-performing biomarkers for distinguishing vitreoretinal lymphoma from in…
New research identifies specific biomarkers that may help doctors more accurately detect and diagnose a rare type of eye cancer.
Multiparametric MRI and image-guided neurointerventions provide critical roles in brain tumor management and surveillance
Advanced Imaging and Interventions Improve Brain Tumor Management
This narrative review examines the roles of advanced diagnostic imaging and image-generated neurointerventions in managing brain tumors, inc…
Newer imaging techniques and minimally invasive procedures are expanding how doctors detect, plan, and treat various types of brain tumors.
EBV prevalence varies widely across lymphoma subtypes, highest in ENKTL at 92.4%
EBV Presence Linked to Lymphoma Cases in People with HIV
This meta-analysis of 307 studies and over 21,140 lymphoma cases quantifies Epstein-Barr virus (EBV) prevalence across lymphoma subtypes, st…
A large review of over 21,000 cases shows that the Epstein-Barr virus is more common in certain lymphoma types among people living with HIV.
CircRNAs act as signaling hubs for immune checkpoints and indicators of ICI response in lymphoma
CircRNAs May Help Predict Response to Lymphoma Immunotherapy
This systematic review examines the role of circRNAs, including EBV-encoded types, in immune evasion within lymphomas. The authors conclude …
New research suggests that specific molecules called circRNAs could help doctors predict how patients with lymphoma will respond to immune c…
EBUS-TBNB yields higher diagnostic rates for lymphoma and sarcoidosis compared to EBUS-TBNA
Core Biopsy Shows Higher Yield for Lymphoma and Sarcoidosis
This meta-analysis of 1434 patients with mediastinal disorders found that EBUS-TBNB provides a significantly higher diagnostic yield for lym…
A core biopsy technique may provide more accurate results than standard needle aspiration for certain conditions like lymphoma and sarcoidos…
Multitarget designs and microenvironment remodeling may overcome resistance to CAR T-cell therapy in B-cell malignancies
New Strategies Identified to Overcome CAR T-cell Therapy Resistance
This systematic review synthesizes current knowledge regarding resistance mechanisms and overcoming strategies for CAR T-cell therapy in rel…
Researchers identified specific ways to overcome resistance in CAR T-cell therapy for patients with certain types of blood cancers.
Narrative review suggests idiotype-directed CAAR-T therapy remains hypothetical for B-cell malignancies
Idiotype-directed CAAR-T therapy remains a hypothesis for B-cell malignancies
This narrative review discusses idiotype-directed CAAR-T therapy for B-cell malignancies including chronic lymphocytic leukemia and indolent…
A narrative review suggests idiotype-directed CAAR-T therapy is a theoretical option for B-cell cancers, not a current treatment.
Systematic review of preclinical CBD effects in canine cancers
Lab tests suggest CBD may help treat cancer in dogs
This is a systematic review of preclinical studies on cannabidiol for canine cancers. It synthesizes evidence of antiproliferative and proap…
Lab tests suggest CBD may help treat cancer in dogs by slowing growth and triggering cell death, though human use remains unproven.
Meta-analysis of double-expressor lymphoma prognoses and novel therapies
Double-expressor lymphoma linked to worse survival outcomes in large study
This systematic evaluation meta-analysis of 9,808 patients with diffuse large B-cell lymphoma found double-expressor lymphoma (DEL) is assoc…
A major review finds double-expressor lymphoma patients have worse survival. New drug combinations show promise for better results.
Tucidinostat plus R-CHOP improves outcomes in MYC/BCL2 double-expressor DLBCL
New drug tucidinostat improves outcomes for high-risk lymphoma patients
A phase 3 trial found adding oral tucidinostat to R-CHOP significantly improved event-free survival and complete response rates in patients …
A large trial shows adding tucidinostat to standard chemo lowers disease risk and improves survival for patients with aggressive lymphoma.
Ven-Chi-Dec Regimen Induces Remission in Refractory Hodgkin Lymphoma
Venetoclax combo shows promise for relapsed Hodgkin lymphoma
A 26-year-old with relapsed/refractory classical Hodgkin lymphoma achieved complete metabolic remission after 6 cycles of venetoclax, chidam…
A 26-year-old man with relapsed Hodgkin lymphoma achieved complete remission after a novel three-drug regimen, with no significant side effe…